Clinical trial
An Open-Label Extension Study to Evaluate the Safety and Efficacy of Oral Methylnaltrexone Bromide Tablets in Subjects With Advanced Pancreatic Cancer
NCT04151719 is registered in ClinicalTrials.gov with Bausch Health Americas, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Extension Study to Evaluate the Safety and Efficacy of Oral Methylnaltrexone Bromide Tablets in Subjects With Advanced Pancreatic Cancer
- Lead sponsor
- Bausch Health Americas, Inc.
- Phase
- Phase 3
- Overall status
- Withdrawn
- Start date
- February 3, 2020
- Completion date
- February 3, 2024
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
pancreatic cancer